Compare ERII & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ERII | VALN |
|---|---|---|
| Founded | 1992 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 740.3M | 855.8M |
| IPO Year | 2008 | 2021 |
| Metric | ERII | VALN |
|---|---|---|
| Price | $14.22 | $10.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $16.50 | $15.75 |
| AVG Volume (30 Days) | ★ 406.0K | 23.7K |
| Earning Date | 02-25-2026 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.56 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | $135,191,000.00 | ★ $211,089,992.00 |
| Revenue This Year | $5.93 | $3.64 |
| Revenue Next Year | $8.97 | $12.23 |
| P/E Ratio | $40.32 | ★ N/A |
| Revenue Growth | 0.10 | ★ 13.48 |
| 52 Week Low | $10.86 | $4.20 |
| 52 Week High | $18.32 | $12.25 |
| Indicator | ERII | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 49.56 | 67.90 |
| Support Level | $14.10 | $9.76 |
| Resistance Level | $14.55 | $10.15 |
| Average True Range (ATR) | 0.35 | 0.33 |
| MACD | 0.07 | 0.17 |
| Stochastic Oscillator | 71.26 | 95.40 |
Energy Recovery Inc is an engineering-driven technology company. It is engaged in engineering, designing, manufacturing and supplying solutions that make industrial processes more efficient and sustainable. The company operates in three segments, Water, Emerging Technologies and Corporate. It offers energy recovery devices (ERDs) and pumps as well as related products and services to the reverse osmosis desalination market. The company derives a majority of the revenue from the Water segment. Geographically, the company operates in the U.S. and other international countries.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.